Family | Therapeutic factor | Trial name | Phase | Administration | Patients with ICM cohort | Number of participants | Main effect |
---|---|---|---|---|---|---|---|
VEGF | VEGF-A165 | VIVA28 | II | IC and intravenous | CCS II–III | 178 | High-dose improved CCS class. Trend in exercise time and angina frequency but not myocardial perfusion |
AdVEGF165 or plasmid/liposome VEGF165 | KAT33 34 | II | IC | CCS II–III for PCI | 103 | Improved myocardial perfusion at 6 months | |
AdVEGF121 | REVASC31 | II | IM minithx | CCS II–IV | 67 | Improved time to 1 mm ST-segment depression on ECG at 26 weeks but not myocardial perfusion | |
AdVEGF121 | NOVA32 | I/II | IM PC | CCS II–IV | 17/129(premature termination) | Negative effect. Premature termination | |
VEGF165 plasmid | EUROINJECT-ONE29 | II/III | IM PC | CCS III–IV | 74 | Negative. No difference in myocardial perfusion | |
VEGF165 plasmid | NORTHERN30 | II/III | IM PC | CCS III–IV | 120 | Negative. No difference in myocardial perfusion | |
FGF | rFGF-2 | Laham et al36 | I/II | Epicardial implantation in ungraftable area | CCS III–IV for CABG | 24 | Improvement in angina symptoms and myocardial perfusion at 3 years with high dose |
rFGF-2 | FIRST37 | II | IC | CCS III–IV | 337 | Trend towards 3 month improvement in angina. No effect on exercise time or myocardial perfusion | |
Ad5-FGF4 | AGENT38 | I/II | IC | CCS II–III | 79 | Improved exercise time | |
Ad5-FGF4 | AGENT-239 | II | IC | CCS II–IV | 52 | Improved myocardial perfusion | |
Ad5-FGF4 | AGENT-340 | III | IC | CCS II–IV | 416 | Negative with a low dose | |
Ad5-FGF4 | AGENT-440 | III | IC | CCS II–IV | 116 | Improved exercise time and tolerance with high dose, only in women |
CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society angina class (I–IV); IC, intracoronary; ICM, ischaemic cardiomyopathy; IM, intramyocardial; minithx, mini-invasive thoracotomy; PC, percutaneous; PCI, percutaneous coronary intervention.